Literature DB >> 26228484

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Marta Celegato1, Cinzia Borghese1, Naike Casagrande1, Maurizio Mongiat1, Xaver U Kahle2, Alice Paulitti1, Michele Spina3, Alfonso Colombatti1, Donatella Aldinucci1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26228484      PMCID： PMC4592277          DOI： 10.1182/blood-2015-07-660365

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Authors:  Donatella Aldinucci; Annunziata Gloghini; Antonio Pinto; Rosaria De Filippi; Antonino Carbone
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

Review 2.  Insights in Hodgkin Lymphoma angiogenesis.

Authors:  Christian Marinaccio; Beatrice Nico; Eugenio Maiorano; Giorgina Specchia; Domenico Ribatti
Journal:  Leuk Res       Date:  2014-06-04       Impact factor: 3.156

3.  Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo.

Authors:  Ming-Fang He; Xiao-Ping Gao; Shu-Chun Li; Zhi-Heng He; Ning Chen; Yu-Bin Wang; Jin-Xiong She
Journal:  Eur J Pharmacol       Date:  2014-07-24       Impact factor: 4.432

4.  Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.

Authors:  Scott J Weir; Louis J DeGennaro; Christopher P Austin
Journal:  Cancer Res       Date:  2012-01-13       Impact factor: 12.701

Review 5.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 6.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

7.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 8.  An update on emerging drugs for Hodgkin lymphoma.

Authors:  Bastian von Tresckow; Volker Diehl
Journal:  Expert Opin Emerg Drugs       Date:  2014-04-21       Impact factor: 4.191

9.  Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.

Authors:  Warren Fiskus; Nakhle Saba; Min Shen; Mondana Ghias; Jinyun Liu; Soumyasri Das Gupta; Lata Chauhan; Rekha Rao; Sumedha Gunewardena; Kevin Schorno; Christopher P Austin; Kami Maddocks; John Byrd; Ari Melnick; Peng Huang; Adrian Wiestner; Kapil N Bhalla
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

10.  Auranofin: repurposing an old drug for a golden new age.

Authors:  Christine Roder; Melanie J Thomson
Journal:  Drugs R D       Date:  2015-03
  10 in total
  16 in total

1.  CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.

Authors:  Sakthi Rajendran; Weng Tong Ho; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

2.  Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.

Authors:  F Linke; M Harenberg; M M Nietert; S Zaunig; F von Bonin; A Arlt; M Szczepanowski; H A Weich; S Lutz; C Dullin; P Janovská; M Krafčíková; L Trantírek; P Ovesná; W Klapper; T Beissbarth; F Alves; V Bryja; L Trümper; J Wilting; D Kube
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

Review 3.  Ferroptosis and Autoimmune Diseases.

Authors:  Benjamin Lai; Chien-Hsiang Wu; Chao-Yi Wu; Shue-Fen Luo; Jenn-Haung Lai
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 4.  Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.

Authors:  Moran Benhar; Iart Luca Shytaj; Jonathan S Stamler; Andrea Savarino
Journal:  J Clin Invest       Date:  2016-05-02       Impact factor: 14.808

5.  Selection and characterization of a human ovarian cancer cell line resistant to auranofin.

Authors:  Luigi Messori; Enrico Mini; Stefania Nobili; Ida Landini; Andrea Lapucci; Alessandro Pratesi; Lara Massai; Cristina Napoli; Gabriele Perrone; Pamela Pinzani
Journal:  Oncotarget       Date:  2017-10-09

Review 6.  New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Authors:  Agnieszka Graczyk-Jarzynka; Radoslaw Zagozdzon; Angelika Muchowicz; Marta Siernicka; Przemyslaw Juszczynski; Malgorzata Firczuk
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

7.  New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.

Authors:  Muhammad Altaf; Muhammad Monim-Ul-Mehboob; Abdel-Nasser Kawde; Giuseppe Corona; Roberto Larcher; Marcia Ogasawara; Naike Casagrande; Marta Celegato; Cinzia Borghese; Zahid H Siddik; Donatella Aldinucci; Anvarhusein A Isab
Journal:  Oncotarget       Date:  2017-01-03

8.  Comparative oncology approach to drug repurposing in osteosarcoma.

Authors:  Alejandro Parrales; Peter McDonald; Megan Ottomeyer; Anuradha Roy; Frank J Shoenen; Melinda Broward; Tyce Bruns; Douglas H Thamm; Scott J Weir; Kathleen A Neville; Tomoo Iwakuma; Joy M Fulbright
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

Review 9.  Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.

Authors:  Donatella Aldinucci; Naike Casagrande
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

10.  Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms.

Authors:  Lei Yang; Hao Wang; Xiang Yang; Qian Wu; Peng An; Xi Jin; Weiwei Liu; Xin Huang; Yuzhu Li; Shiyu Yan; Shuying Shen; Tingbo Liang; Junxia Min; Fudi Wang
Journal:  Signal Transduct Target Ther       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.